DPP4 and type 2 diabetes mellitus: Currently, GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors of GLP-1 degradation have been identified as pharmacological targets for the treatment of type 2 diabetes, as well as to promote satiety and body weight loss [102].